How to appeal a UnitedHealthcare severe acne denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for severe acne

Cited policy: UHC Commercial Medical Benefit Drug Policy — Isotretinoin (Claravis / Amnesteem / Myorisan / Zenatane / Absorica / Absorica LD)

Severe recalcitrant nodular acne OR moderate acne with scarring / significant psychosocial impact. Failure / intolerance of >=1 oral antibiotic + topical retinoid + BPO >=3 months. iPledge enrollment mandatory. Absorica LD requires documented inability to consistently take with high-fat meal. Reauth annually.

How UnitedHealthcare denies severe acne — and how to counter it

Where UnitedHealthcare pushes back: 1) Try doxycycline 12 weeks first; 2) Use compounded isotretinoin; 3) Generic equivalent for Absorica LD.

Counter-arguments that hold up: AAD 2024 Recommendation 11 — scarring or psychosocial impact justifies first-line isotretinoin without antibiotic trial (Reynolds J Am Acad Dermatol 2024). NO FDA-approved compounded isotretinoin — iPledge REMS prohibits non-REMS product (21 CFR 314 violation). Absorica LD lidose-micronized formulation achieves fasted-state bioequivalence (FDA Jan 31, 2020) — document variable meal compliance. Cite Leyden 2014 for cumulative dose target 120-150 mg/kg.

What UnitedHealthcare typically denies for severe acne

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For severe acne, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the severe acne treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Isotretinoin (generic)
• Absorica LD
• Doxycycline
• Minocycline / Solodyn
• Seysara
• Aklief

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.